Sanjivani Paranteral Limited And Hindustan Antibiotics Limited Collaborate

Sanjivani Paranteral Limited, a pharmaceutical company specialising in the manufacturing and distribution of high-quality parenteral and oral solid products, has inked a significant agreement with Hindustan Antibiotics Limited for the manufacturing of IV formulations and IV Sets. The agreement is backed by a confirmed purchase commitment from Hindustan Antibiotics Limited.

The partnership will see the establishment of a cutting-edge manufacturing facility within the premises of Hindustan Antibiotics Limited at Pimpri works, Pune, Maharashtra. Sanjivani Paranteral will soon initiate the process of upgrading facilities, the production is likely to start from Q3FY25. The plant capacity will be 50 lakh IV fluids bottles and 10 lakh IV sets per month. This strategic move underlines both companies' commitment to meet the demand of IV formulations and IV sets. The total investment for the project would be Rs 50 Crores.

"Our aim is to build a world-class organization grounded in Passion, Performance, and Partnership," said Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Paranteral Ltd. "Our collaboration with Hindustan Antibiotics Limited not only reaffirms our commitment to innovation and healthcare quality but also aligns with our vision for advancing pharmaceutical manufacturing in India. We believe that by contributing to 'Make in India,' we can significantly impact the evolution of IV formulations and IV Sets, ultimately benefiting patients and healthcare providers."

Speaking on the partnership, Mr. Milind Palhade from Hindustan Antibiotics Ltd, said, “This partnership epitomizes our commitment to fostering innovation and maintaining high-quality standards in the healthcare sector. We firmly believe that our combined capabilities will make a substantial contribution to the progression. The joint venture will help to elevate the standards of pharmaceutical manufacturing, emphasizing innovation, quality, and accessibility in the production of IV formulations and IV Sets. Both the companies are positive about the transformative impact this collaboration will have on healthcare delivery in India.”